ArticleBlood advances2024

Venetoclax-rituximab is active in patients with BTKi-exposed CLL, but durable treatment-free remissions are uncommon.

Thomas E Lew et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.